SCHOTT PHARMA : UBS reiterates its Neutral rating : comparem

Initially Neutral on the company, UBS's analyst Olivier Calvet maintained his recommendation. The target price is decreased from EUR 40 to EUR 33.

Related Keywords

Olivier Calvet , , Initially Neutral ,